Alterity Therapeutics Limited
PRNAF
$0.01
$0.00-44.55%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 920.00K | 917.10K | 1.23M | 1.20M | 523.20K |
| Total Revenue | 920.00K | 917.10K | 1.23M | 1.20M | 523.20K |
| Cost of Revenue | 32.40K | 32.30K | 20.50K | 20.10K | 20.70K |
| Gross Profit | 887.60K | 884.70K | 1.21M | 1.18M | 502.50K |
| SG&A Expenses | 1.68M | 1.67M | 695.30K | 680.90K | 1.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 62.80K | 62.60K | 9.80K | 9.60K | 18.40K |
| Total Operating Expenses | 4.35M | 4.33M | 3.51M | 3.44M | 2.98M |
| Operating Income | -3.43M | -3.42M | -2.28M | -2.23M | -2.46M |
| Income Before Tax | -3.14M | -3.13M | -1.57M | -1.54M | -2.34M |
| Income Tax Expenses | 20.20K | 20.10K | 21.80K | 21.30K | -- |
| Earnings from Continuing Operations | -3.16M | -3.15M | -1.59M | -1.56M | -2.34M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.16M | -3.15M | -1.59M | -1.56M | -2.34M |
| EBIT | -3.43M | -3.42M | -2.28M | -2.23M | -2.46M |
| EBITDA | -3.43M | -3.42M | -2.28M | -2.23M | -2.45M |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 10.18B | 10.18B | 7.48B | 7.48B | 5.31B |
| Average Diluted Shares Outstanding | 10.18B | 10.18B | 7.48B | 7.48B | 5.31B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |